Administration frequency as well as dosage of PTH are associated with development of cortical porosity in ovariectomized rats

Takakura, Aya; Lee, Jiwon; Hirano, Kyoko; Isogai, Yukihiro; Ishizuya, Toshinori; Takao-Kawabata, Ryoko; Iimura, Tadahiro

doi:10.1038/boneres.2017.2

Cited by 31 publications

(31 citation statements)

References 54 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[30] Additionally, cortical porosity involving intracortical resorption in ovariectomized rat was shown to be caused by PTH, and its effect was shown to increase with increasing dosage and frequency. [31] Movement in the normal dose PTH (PTH-1_N; 56.5 µg per week) group may have been in uenced by the effect of PTH on cortical porosity. Higher BV/TV and Tb.Th values relating bone density and bone mass may also explain implant movement in the PTH-1_N group.…”

Section: Discussionmentioning

confidence: 99%

Effect of PTH and corticotomy on implant movement under mechanical force

Kim

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Osseointegrated implants are considered as clinically non-movable. Parathyroid hormone (PTH) is known to play a significant role in the regulation of bone remodeling and in intermittent, low doses, result in osteoanabolic effects. This study aimed to investigate the effects of PTH and corticotomy, both under traction force, on osseointegrated implants. Methods Four implants—two in each hemimandible—were placed in each of the three study mongrels. Each mongrels were designated as control, normal dose PTH (PTH-1), and high dose PTH (PTH-2) groups, with each groups further subdivided into non-surgery and surgery groups. After osseointegration, mechanical force with NiTi closed coil springs (500g) was applied around each implants. Corticotomy was performed around one of four implants in each mongrels. Parathyroid hormone was administered locally on a weekly basis for 20 weeks. Clinical movement of the implants were evaluated with the superimposed 3D- scanned data, bone- microarchitectural and histologic examinations Results Superimposition analysis showed continuous movement of the implants in PTH-1 group. Movement was further justified with lowest bone implant contact (adjusted BIC; 44.77%) in histomorphometric analysis. Upregulation of bone remodeling around the implant was observed in the normal dose PTH group. In the surgery subgroups, the remarkably higher adjusted BIC compared to the non-surgery subgroups indicated increased bone formation around the implant surface. Conclusion The results indicate that the balance of osseointegrated implants in bone remodeling can be shifted via various interventions. Clinical Relevance Upregulated bone remodeling by PTH and corticotomy under continuous mechanical force showed the possible implications on the clinical implant movement.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of PTH and corticotomy on implant movement under mechanical force

Kim

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Generally, BMD of the spine, which consists mostly cancellous bone, improved well after osteoporotic treatment. TPTD is well known for improving cancellous bone density and reducing cortical porosity [14,15]. Therefore, the short term TPTD therapy was able to affect cancellous bone, whereas it was too short to reduce cortical porosity.…”

Section: Discussionmentioning

confidence: 99%

The Impact of Switching from Short-Term Teriparatide Treatment to Denosumab Therapy Compared with Denosumab Alone for Patients with Osteoporotic Hip Fracture: A 1-Year Follow-up Study

Park¹,

Yoo²,

Park³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Switching the prescription from bone-forming medication to resorptive agents is reportedly effective for patients with severe osteoporosis. The objective of this study is to determine the impact of implementing short-term teriparatide (TPTD) intervention before denosumab (DMab) therapy compared with DMab therapy alone for 1 year after hip fracture.Methods: TPTD was administered to 24 patients for an average of 12.1 weeks after which the intervention was switched to DMab therapy for 12 months (group 1). DMab alone was administered to 16 patients for 12 months (group 2). Bone mineral density (BMD) was evaluated before and after treatment at the 1-year follow-up. The improvement of BMD and T-score in hip and spine was compared with the levels of bone turnover marker.Results: The difference of hip BMD after osteoporosis treatment was -0.0081±0.03 in group 1 and 0.0074±0.04 in group 2 (p=0.180). The difference of spine BMD was 0.0819±0.04 in group 1 and 0.0145±0.03 in group 2 (p<0.001). BMD and T-score of the spine improved significantly in groups 1 and 2 (p < 0.001). There was no statistical difference in C-terminal telopeptide and osteocalcin level. Conclusion: Short-term TPTD administration followed by DMab alone was effective only in improving spine BMD. Short-term treatment with TPTD caused mild improvement in femur neck BMD compared with DMab alone. However, further research with a longer duration of TPTD treatment is warranted, as our findings lack statistical significance.

show abstract

“…Generally, BMD of the spine, which consists mostly cancellous bone, improved easilty after osteoporotic treatment. TPTD is well known for improving cancellous bone density and reducing cortical porosity [14,15]. Therefore, the short term TPTD therapy was able to affect cancellous bone, whereas it was too short to reduce cortical porosity.…”

Section: Discussionmentioning

confidence: 99%

The impact of sequential therapy from short-term teriparatide to denosumab compared with denosumab alone in patients with osteoporotic hip fracture: A 1-year follow-up study

Park

Yoo

Park

et al. 2020

Preprint

View full text Add to dashboard Cite

Background : Sequential therapy from bone-forming medication to resorptive agents is reportedly effective for patients with severe osteoporosis. The objective of this study is to determine the impact of implementing short-term teriparatide (TPTD) intervention before denosumab (DMab) therapy compared with DMab therapy alone for 1 year after hip fracture. Methods : TPTD was administered to 22 patients for an average of 12.1 weeks after which the intervention was switched to DMab therapy for 12 months (group 1). DMab alone was administered to 16 patients for 12 months (group 2). Bone mineral density (BMD) was evaluated before and after treatment at the 1-year follow-up. The improvement of BMD in hip and spine was compared with the levels of bone turnover marker.Results: The difference in femoral neck BMD was 0.0049±0.04 in group 1 and -0.0139±0.10 in group 2 (p=0.442). The difference of spine BMD was 0.0433±0.05 in group 1 and 0.0515±0.06 in group 2 (p=0.640). BMD of the spine improved significantly in groups 1 and 2 (p < 0.001, 0=0.002). There was no statistical difference in C-terminal telopeptide and osteocalcin level. Conclusion : Short-term TPTD administration followed by DMab alone was effective only in improving spine BMD. Short-term treatment with TPTD caused mild improvement in femur neck BMD compared with DMab alone. However, further research with a longer duration of TPTD treatment is warranted, as our findings lack statistical significance.

show abstract

Administration frequency as well as dosage of PTH are associated with development of cortical porosity in ovariectomized rats

Cited by 31 publications

References 54 publications

Effect of PTH and corticotomy on implant movement under mechanical force

Effect of PTH and corticotomy on implant movement under mechanical force

The Impact of Switching from Short-Term Teriparatide Treatment to Denosumab Therapy Compared with Denosumab Alone for Patients with Osteoporotic Hip Fracture: A 1-Year Follow-up Study

The impact of sequential therapy from short-term teriparatide to denosumab compared with denosumab alone in patients with osteoporotic hip fracture: A 1-year follow-up study

Contact Info

Product

Resources

About